HLA class I histocompatibility antigen, C alpha chain (HLA-C*08:01) (HLA-C*08:01)

HLA-C*08:01 is a specific allele of the Human Leukocyte Antigen C (HLA-C) gene, which encodes a Major Histocompatibility Complex (MHC) class I heavy chain (hlaprotein.com, nih.gov). This molecule forms a heterodimer with beta-2 microglobulin to present intracellularly derived peptides, typically 9 amino acids in length, to CD8+ cytotoxic T cells (cancer.gov). It also serves as a ligand for killer cell immunoglobulin-like receptors (KIRs) on natural killer (NK) cells, thereby modulating both adaptive and innate immune responses (nih.gov). In clinical oncology, HLA-C*08:01 is a critical restriction element for TCR-T cell therapies targeting the KRAS G12D neoantigen, particularly in pancreatic and colorectal cancers (nih.gov, cancer.gov). Beyond its role in cancer immunotherapy, the allele is associated with the immune control of viral infections such as HIV-1 and HBV (nih.gov). It is also linked to susceptibility to certain autoimmune conditions like psoriasis and psoriatic arthritis (nih.gov). Furthermore, HLA-C*08:01 is associated with severe drug-induced hypersensitivity reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), when interacting with medications like co-trimoxazole (frontiersin.org). Therapeutic strategies involving this target primarily focus on engineering T cells to recognize specific neoantigens presented by the HLA-C*08:01 molecule to achieve targeted tumor destruction (cancer.gov).

Other names

HLA-C*0801HLA-Cw8Cw*08:01Cw0801MHC class I antigen C*08:01HLA class I histocompatibility antigen, C alpha chain

HLA-C*08:01 presents intracellular peptides, such as the KRAS G12D neoantigen, to the T-cell receptors (TCRs) of CD8+ cytotoxic T cells, facilitating targeted immune-mediated cell lysis. It also interacts with killer cell immunoglobulin-like receptors (KIRs) on natural killer cells to modulate innate immunity.